DMAA is a stimulant, for which a safe level for human consumption has not been established. Products containing DMAA have been withdrawn in various countries across the European Union and around the world. DMAA has been linked with high blood pressure, nausea, cerebral haemorrhage, stroke and death.
Where DMAA is present in a product it may be listed on the packaging as:
- 1,3-dimethylamylamine
- DMAA
- geranium extract
- geranamine
- methylhexanamine
- 4-methylhexane-2-amine
The FSA is working closely with enforcement authorities to ensure that food supplements containing DMAA are not on sale in shops. Consumers are also advised not to buy online any food supplements or products containing DMAA. If you have consumed products containing DMAA and you feel unwell, please contact your GP.
An independent advisory panel has been asked by the Medicines and Healthcare products Regulatory Agency (MHRA) to advise whether a certain product containing DMAA should be classed as an unlicensed medicine and therefore subject to medicine controls. This advice may also have implications for the status of other DMAA-containing supplements.
